Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R21) | Apply Online

Opportunity Summary:

The grant opportunity titled "Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R21)" (RFA-AR-17-004) is a National Institutes of Health funding announcement under HHS/NIH, aligned with the mission of NIAMS (the National Institute of Arthritis and Musculoskeletal and Skin Diseases). It is designed to support smaller, focused research projects that add a mechanistic "layer" onto an interventional clinical trial that is already underway and funded through other sources (either public or private). The central idea is to take advantage of an existing trial's built-in strengths such as its enrolled participants, clinical infrastructure, structured data collection, and available biospecimens so that investigators can answer deeper biological or pathophysiological questions without needing to build a new trial from scratch.

A defining feature of this program is that it only supports ancillary studies that are tied to an ongoing parent interventional clinical trial. In practical terms, the parent trial must already be recruiting participants or actively following them and must be able to provide a well-characterized cohort, along with the operational capacity to integrate the proposed ancillary procedures or analyses. Because the opportunity is framed around interventional clinical trials, the parent project needs to involve an intervention (for example, a drug, biologic, device, behavioral treatment, or other therapeutic strategy) rather than being purely observational. The ancillary study is not meant to replace or duplicate the parent trial's primary outcomes; instead, it is meant to explain how and why an intervention works (or does not work), identify biological pathways affected by treatment, clarify disease mechanisms, or uncover markers that predict response, toxicity, or disease progression within conditions relevant to the NIAMS portfolio.

The FOA emphasizes "time-sensitive" mechanistic research, meaning the proposed ancillary work needs to be done while the parent trial is still active and while critical windows for sample collection and measurement are still available. To match that urgency, applications submitted to this opportunity are reviewed and awarded using an accelerated process. Applicants are expected to clearly justify why the work cannot wait for a standard grant cycle and why it must be launched quickly to capitalize on the parent trial's remaining timeline. A strong application, in other words, makes a credible case that missing the parent trial's enrollment period, intervention phase, follow-up visits, or scheduled biospecimen collections would materially weaken or eliminate the opportunity to answer the mechanistic question.

To keep the proposal grounded and feasible, each application is expected to lay out a clear mechanistic rationale and premise. That means the investigators should articulate the specific biological mechanism they intend to probe, why it is plausible based on existing evidence, and how the ancillary measurements will generate interpretable data in the context of the intervention being tested. The FOA also requires a detailed timeline demonstrating that the parent trial has enough time left to incorporate the ancillary study activities, whether those activities involve additional assays on stored samples, new collections during upcoming visits, imaging, immune profiling, genetic or transcriptomic analysis, biomarker development, or other mechanistic endpoints. Alongside the scientific plan, applicants must document permission from the parent trial leadership to access and use the trial's participant cohort, data, and biological materials. This is a practical requirement meant to ensure that data access, specimen availability, and trial operations are truly in place rather than assumed.

The broader purpose of the program is efficiency and leverage. NIH is explicitly trying to maximize the return on existing investments by using trials that already have recruitment pipelines, standardized data capture, and established governance structures. By adding a carefully designed mechanistic ancillary study, the funded work can increase the scientific yield of the parent trial beyond the primary clinical endpoints, producing insights that help the field understand disease biology or organ system function within the NIAMS mission area. Ideally, the mechanistic results generated through this R21 mechanism can point toward novel diagnostic approaches, new therapeutic targets, improved treatment selection, or prevention strategies, all while keeping costs and timelines more manageable than launching a new standalone clinical study.

From an administrative standpoint, this is a discretionary grant opportunity with a health funding activity category (CFDA 93.846). The award ceiling listed is $250,000, consistent with an R21-style exploratory or developmental project that is typically scoped to be targeted and time-limited. The eligible applicant pool is broad and includes many common research institutions and organizations, such as public and private institutions of higher education, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), for-profit organizations (including small businesses and other for-profits), and various government entities including state, county, city/township governments, special districts, independent school districts, public housing authorities, and eligible Native American tribal governments and organizations. The FOA was posted on February 5, 2016, with a closing date of April 3, 2017, reflecting a defined application window for proposals seeking to attach to eligible ongoing trials during that period.

In summary, this opportunity funds fast-moving, mechanistically focused ancillary studies that piggyback on active interventional clinical trials relevant to NIAMS. It is built for situations where the scientific question is compelling but the opportunity to answer it is fleeting because it depends on a trial that is already in motion. The key expectations are a strong mechanistic hypothesis, a feasible integration plan tied to the parent trial schedule, a clear explanation of why speed matters, and documented authorization to use the parent trial's participants, data, and biospecimens.

Browse more opportunities from the same agency: HHS-NIH11

Browse more opportunities from the same category: Health

Next opportunity: Fetal Alcohol Spectrum Disorders Practice and Implementation Centers

Previous opportunity: Notice of Intent to Award: SCA Conservation Interns – Weir Farm National Historic Site

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA AR 17 004

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA AR 17 004) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA AR 17 004", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.